Evidence supporting the use of: Potassium
For the health condition: Radiation Sickness

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 4

Potassium, specifically in the form of potassium iodide (KI), is scientifically validated for use in the context of radiation exposure, but with a particular focus: it is not a treatment for general radiation sickness, but rather a prophylactic agent to prevent the uptake of radioactive iodine by the thyroid gland. In the event of a nuclear accident or radiological emergency, radioactive iodine (especially iodine-131) may be released into the environment. If inhaled or ingested, this isotope can accumulate in the thyroid and significantly increase the risk of thyroid cancer, particularly in children. The administration of potassium iodide saturates the thyroid with stable (non-radioactive) iodine, thereby reducing or blocking the absorption of radioactive iodine. This protective effect is well-supported by scientific studies and is endorsed by organizations such as the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), and the US Food and Drug Administration (FDA). The effectiveness of KI depends on the timing of administration—it is most effective if taken shortly before or immediately after exposure to radioactive iodine. However, potassium (as potassium chloride or other salts) does not mitigate the effects of other radioactive elements (like cesium or strontium) nor does it treat the systemic symptoms of radiation sickness (acute radiation syndrome), which results from damage to rapidly dividing cells throughout the body. Thus, potassium's role is highly specific and evidence-based for thyroid protection in radioactive iodine exposure, not for general radiation sickness.

More about potassium
More about Radiation Sickness